These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 33973222)

  • 1. [Pharmacogenomics - a cornerstone of Precision Medicine. Genomic Medicine Sweden analyses genotypes associated with serious drug toxicity or therapeutic failure].
    Eliasson E; Wadelius M
    Lakartidningen; 2021 May; 118():. PubMed ID: 33973222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomics of Adverse Drug Reactions.
    Alfirevic A; Pirmohamed M
    Trends Pharmacol Sci; 2017 Jan; 38(1):100-109. PubMed ID: 27955861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Genomic Medicine Sweden - a national initiative for the broad introduction of precision medicine in Swedish healthcare].
    Edsjö A; Friedman M; Rosenquist R
    Lakartidningen; 2021 May; 118():. PubMed ID: 33977514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenomics and Global Precision Medicine in the Context of Adverse Drug Reactions: Top 10 Opportunities and Challenges for the Next Decade.
    Alessandrini M; Chaudhry M; Dodgen TM; Pepper MS
    OMICS; 2016 Oct; 20(10):593-603. PubMed ID: 27643672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenetics, pharmacogenomics, and individualized medicine.
    Ma Q; Lu AY
    Pharmacol Rev; 2011 Jun; 63(2):437-59. PubMed ID: 21436344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenomics: Precision Medicine and Drug Response.
    Weinshilboum RM; Wang L
    Mayo Clin Proc; 2017 Nov; 92(11):1711-1722. PubMed ID: 29101939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenomics: Prescribing Precisely.
    Wake DT; Ilbawi N; Dunnenberger HM; Hulick PJ
    Med Clin North Am; 2019 Nov; 103(6):977-990. PubMed ID: 31582008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Canadian Pharmacogenomics Network for Drug Safety: a model for safety pharmacology.
    Ross CJ; Visscher H; Sistonen J; Brunham LR; Pussegoda K; Loo TT; Rieder MJ; Koren G; Carleton BC; Hayden MR;
    Thyroid; 2010 Jul; 20(7):681-7. PubMed ID: 20578893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenomics of adverse drug reactions: practical applications and perspectives.
    Becquemont L
    Pharmacogenomics; 2009 Jun; 10(6):961-9. PubMed ID: 19530963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Report on the pharmacogenomics and personalized medicine 2011 conference: part 1.
    Harrison N
    Pharmacogenomics; 2012 Jan; 13(2):141-5. PubMed ID: 22256866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Personalized Medicine and Adverse Drug Reactions: The Experience of An Italian Teaching Hospital.
    La Russa R; Fineschi V; Di Sanzo M; Gatto V; Santurro A; Martini G; Scopetti M; Frati P
    Curr Pharm Biotechnol; 2017; 18(3):274-281. PubMed ID: 28176638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers.
    Dunnenberger HM; Crews KR; Hoffman JM; Caudle KE; Broeckel U; Howard SC; Hunkler RJ; Klein TE; Evans WE; Relling MV
    Annu Rev Pharmacol Toxicol; 2015; 55():89-106. PubMed ID: 25292429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Attitudes of clinicians following large-scale pharmacogenomics implementation.
    Peterson JF; Field JR; Shi Y; Schildcrout JS; Denny JC; McGregor TL; Van Driest SL; Pulley JM; Lubin IM; Laposata M; Roden DM; Clayton EW
    Pharmacogenomics J; 2016 Aug; 16(4):393-8. PubMed ID: 26261062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. General considerations for integrating pharmacogenomics into mainstream medical practice.
    Patrinos GP
    Hum Genomics; 2010 Aug; 4(6):371-4. PubMed ID: 20846925
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical Utility and Economic Impact of CYP2D6 Genotyping.
    Reynolds KK; McNally BA; Linder MW
    Clin Lab Med; 2016 Sep; 36(3):525-42. PubMed ID: 27514466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Opportunities and Challenges in Cardiovascular Pharmacogenomics: From Discovery to Implementation.
    Roden DM; Van Driest SL; Wells QS; Mosley JD; Denny JC; Peterson JF
    Circ Res; 2018 Apr; 122(9):1176-1190. PubMed ID: 29700066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advancing Pharmacogenomics from Single-Gene to Preemptive Testing.
    Haidar CE; Crews KR; Hoffman JM; Relling MV; Caudle KE
    Annu Rev Genomics Hum Genet; 2022 Aug; 23():449-473. PubMed ID: 35537468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenomics and Personalized Medicine.
    Cecchin E; Stocco G
    Genes (Basel); 2020 Jun; 11(6):. PubMed ID: 32580376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of pharmacogenomics in elderly patients treated for cardiovascular diseases.
    Božina N; Vrkić Kirhmajer M; Šimičević L; Ganoci L; Mirošević Skvrce N; Klarica Domjanović I; Merćep I
    Croat Med J; 2020 Apr; 61(2):147-158. PubMed ID: 32378381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DruGeVar: an online resource triangulating drugs with genes and genomic biomarkers for clinical pharmacogenomics.
    Dalabira E; Viennas E; Daki E; Komianou A; Bartsakoulia M; Poulas K; Katsila T; Tzimas G; Patrinos GP
    Public Health Genomics; 2014; 17(5-6):265-71. PubMed ID: 25228099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.